This regulatory milestone acknowledges the adaptability of the AdenoVerse platform, which is already utilized in the treatment of recurrent respiratory papillomatosis. By securing this designation, Precigen gains a structured pathway to reduce redundant development work. The company can now utilize existing preclinical knowledge and manufacturing insights to accelerate regulatory reviews for upcoming product candidates, including those targeting HPV-associated malignancies like cervical and oropharyngeal cancers.

To qualify for this status, a platform must demonstrate consistent performance, safety, and reproducibility across multiple applications. The FDA determined that AdenoVerse meets these criteria, offering the company opportunities for early and frequent agency engagement. Helen Sabzevari, Precigen’s President and CEO, noted that the designation will be particularly impactful for the development of PRGN-2009. The company intends to apply these efficiency gains across its broader portfolio, aiming for greater predictability as it advances treatments from clinical study stages toward potential commercialization.